- Home
- SNTG vs XRTX Comparison
SNTG vs XRTX Comparison
Compare SNTG & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNTG
- XRTX
- Stock Information
- Founded
- SNTG 2009
- XRTX 2011
- Country
- SNTG China
- XRTX Canada
- Employees
- SNTG N/A
- XRTX N/A
- Industry
- SNTG Finance: Consumer Services
- XRTX Pharmaceuticals and Biotechnology
- Sector
- SNTG Finance
- XRTX Health Care
- Exchange
- SNTG Nasdaq
- XRTX Nasdaq
- Market Cap
- SNTG 4.8M
- XRTX 4.2M
- IPO Year
- SNTG 2021
- XRTX N/A
- Fundamental
- Price
- SNTG $3.06
- XRTX $0.84
- Analyst Decision
- SNTG
- XRTX
- Analyst Count
- SNTG 0
- XRTX 0
- Target Price
- SNTG N/A
- XRTX N/A
- AVG Volume (30 Days)
- SNTG 4.6M
- XRTX 42.6K
- Earning Date
- SNTG 05-14-2025
- XRTX 11-14-2025
- Dividend Yield
- SNTG N/A
- XRTX N/A
- EPS Growth
- SNTG N/A
- XRTX N/A
- EPS
- SNTG N/A
- XRTX N/A
- Revenue
- SNTG $107,507.00
- XRTX N/A
- Revenue This Year
- SNTG N/A
- XRTX N/A
- Revenue Next Year
- SNTG N/A
- XRTX N/A
- P/E Ratio
- SNTG N/A
- XRTX N/A
- Revenue Growth
- SNTG N/A
- XRTX N/A
- 52 Week Low
- SNTG $1.43
- XRTX $0.66
- 52 Week High
- SNTG $12.70
- XRTX $2.51
- Technical
- Relative Strength Index (RSI)
- SNTG 52.40
- XRTX 56.66
- Support Level
- SNTG N/A
- XRTX $0.80
- Resistance Level
- SNTG $6.90
- XRTX $0.86
- Average True Range (ATR)
- SNTG 1.58
- XRTX 0.04
- MACD
- SNTG -0.10
- XRTX 0.01
- Stochastic Oscillator
- SNTG 23.54
- XRTX 100.00
About SNTG Sentage Holdings Inc.
Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.